Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accumulated Expenses (2016 - 2022)

Cumberland Pharmaceuticals' Accumulated Expenses history spans 12 years, with the latest figure at $17.6 million for Q4 2022.

  • For Q4 2022, Accumulated Expenses rose 102.9% year-over-year to $17.6 million; the TTM value through Dec 2022 reached $17.6 million, up 102.9%, while the annual FY2022 figure was $17.6 million, 102.9% up from the prior year.
  • Accumulated Expenses for Q4 2022 was $17.6 million at Cumberland Pharmaceuticals, up from $8.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $17.6 million in Q4 2022 and bottomed at $8.7 million in Q4 2021.
  • The 5-year median for Accumulated Expenses is $11.3 million (2020), against an average of $13.1 million.
  • The largest annual shift saw Accumulated Expenses crashed 33.67% in 2019 before it skyrocketed 102.9% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $16.7 million in 2018, then plummeted by 33.67% to $11.1 million in 2019, then grew by 1.53% to $11.3 million in 2020, then decreased by 22.98% to $8.7 million in 2021, then surged by 102.9% to $17.6 million in 2022.
  • Per Business Quant, the three most recent readings for CPIX's Accumulated Expenses are $17.6 million (Q4 2022), $8.7 million (Q4 2021), and $11.3 million (Q4 2020).